New drug combo targets tough lung cancer

NCT ID NCT05815173

Recruiting now Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 08, 2026 · Updated 19 times

Summary

This study tests two oral drugs, ladarixin and sotorasib, in people with advanced KRAS G12C mutant non-small cell lung cancer. The goal is to see if the combination is safe and helps control the cancer for longer. About 40 adults with this specific genetic mutation will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NYU Langone Health
RECRUITING

Garden City, New York, 11530, United States
NYU Langone Health
RECRUITING

Mineola, New York, 11501, United States
NYU Langone Health
RECRUITING

New Hyde Park, New York, 11042, United States
NYU Langone Health
RECRUITING

New York, New York, 10010, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
NYU Langone Health
RECRUITING

New York, New York, 10017, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION